FDA Approves Gilead Sciences, Inc.'s Once-Daily Single Tablet HIV-1 Regimen

U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen CompleraA for Patients Switching from a Stable Regimen FOSTER CITY, Calif.-- --Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen CompleraA for use in certain virologically-suppressed .

http://www.biospace.com/news_story.aspx?StoryID=318686&full=1